MedTrace Logo

Tricaprilin in Mild to Moderate Alzheimer's Disease

NCT00142805 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2020-09-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability and effectiveness of tricaprilin administered once a day for ninety days in subjects with mild to moderate, probable Alzheimer's disease.

Conditions

Interventions

DRUG

Tricaprilin

Powder formulation will be mixed in a liquid (approximately 8 oz).

OTHER

Placebo

Powder formulation will be mixed in a liquid (approximately 8 oz).

Sponsors & Collaborators

  • Cerecin

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-04
Primary Completion
2006-06-29
Completion
2007-01-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00142805 on ClinicalTrials.gov